Factors associated with serum fetuin-A concentrations after long-term use of different phosphate binders in hemodialysis patients

Hsin-Hung Lin, Hung-Hsiang Liou, Ming-Shiou Wu, Chiu-Ching Huang, Hsin-Hung Lin, Hung-Hsiang Liou, Ming-Shiou Wu, Chiu-Ching Huang

Abstract

Background: Fetuin-A is known as a circulating inhibitor of vascular calcification. Factors associated with serum fetuin-A concentrations after long-term use of different phosphate binders in hemodialysis patients is still uncertain.

Methods: In the post-hoc study, we analyzed serum fetuin-A and biochemical factors (Ca, P, i-PTH, hsCRP, TG, LDL-C) in 50 hemodialysis patients, who completed a 48-week, open-Label, controlled randomized parallel-group study. 23 patients received sevelamer and 27 patients received calcium carbonate.

Results: After the 48-week treatment, the sevelamer group had less serum calcium increment, less iPTH decrement, more ALK-P increment, more hsCRP decrement and more LDL-C decrement. There was no significant difference in the serum fetuin-A decrement between two groups. Decreased serum fetuin-A levels were found after 48-week treatment in both groups: from 210.61 (104.73) to 153.85 (38.64) ug/dl, P = 0.003 in sevelamer group, from 203.95 (107.87) to 170.90 (58.02) ug/mL, P =0.002 in calcium group. The decrement in serum fetuin-A (Δfetuin-A) levels was associated with ΔCa (ρ = - 0.230, P = 0.040), ΔiPTH (ρ = 0.306, P = 0.031) and Δalbumin (ρ = 0.408, P = 0.003), not associated with sevelamer use, ΔP and ΔhsCRP.

Conclusion: After long-term sevelamer or calcium carbonate treatment, both groups of maintenance HD patients had lower serum fetuin-A levels. Serum levels of increased calcium, decreased iPTH and decreased albumin were associated with the serum fetuin-A decrement.

Trial registration: ClinicalTrials.gov NCT01755078.

Keywords: CKD; ESRD; Fetuin-A; Hemodialysis; Phosphate binder; Sevelamer.

Figures

Fig. 1
Fig. 1
Patient flow chart

References

    1. Goodman WG, London G, Amann K, Block GA, Giachelli C, Hruska KA, et al. Vascular Calcification Work Group: Vascular calcification in chronic kidney disease. Am J Kidney Dis. 2011;43:572–579. doi: 10.1053/j.ajkd.2003.12.005.
    1. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis. 1998;31(4):607–617. doi: 10.1053/ajkd.1998.v31.pm9531176.
    1. Hruska KA, Mathew S, Lund R, Qiu P, Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney Int. 2008;74:148–157. doi: 10.1038/ki.2008.130.
    1. Scialla JJ, Kao WH, Crainiceanu C, Sozio SM, Oberai PC, Shafi T, et al. Biomarkers of vascular calcification and mortality in patients with ESRD. Clin J Am Soc Nephrol. 2014;9:745–755. doi: 10.2215/CJN.05450513.
    1. Liabeuf S, Okazaki H, Desjardins L, Fliser D, Goldsmith D, Covic A, et al. Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario? Nephrol Dial Transplant. 2014;29:1275–1284. doi: 10.1093/ndt/gft368.
    1. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Böhm R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A cross-sectional study. Lancet. 2003;361:827–833. doi: 10.1016/S0140-6736(03)12710-9.
    1. Jung HH, Baek HJ, Kim SW. Fetuin-A, coronary artery calcification and outcome in maintenance hemodialysis patients. Clin Nephrol. 2011;75(5):391–396. doi: 10.5414/CNP75391.
    1. Jahnen-Dechent W, Schäfer C, Heiss A, Grötzinger J. Systemic inhibition of spontaneous calcification by the serum protein alpha 2-HS glycoprotein/fetuin. Z Kardiol. 2001;90(suppl 3):47–56.
    1. Gangneux C, Daveau M, Hiron M, Derambure C, Papaconstantinou J, Salier JP. The inflammation-induced downregulation of plasma Fetuin-A (alpha2HS- glycoprotein) in liver results from the loss of interaction between long C/EBP isoforms at two neighbouring binding sites. Nucleic Acids Res. 2003;31(20):5957–5970. doi: 10.1093/nar/gkg788.
    1. Brylka L, Jahnen-Dechent W. The role of fetuin-A in physiological and pathological mineralization. Calcif Tissue Int. 2013;93(4):355–364. doi: 10.1007/s00223-012-9690-6.
    1. Jahnen-Dechent W, Heiss A, Schafer C, Ketteler M. Fetuin- A regulation of calcified matrix metabolism. Circ Res. 2011;108:1494–1509. doi: 10.1161/CIRCRESAHA.110.234260.
    1. Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62(1):245–252. doi: 10.1046/j.1523-1755.2002.00434.x.
    1. Raggi P, Vukicevic S, Moyses RM, Wesseling K, Spiegel DM. Ten-year experience with sevelamer and calcium salts as phosphate binders. Clin J Am Soc Nephrol. 2010;5(Suppl 1):S31–40. doi: 10.2215/CJN.05880809.
    1. Iimori S, Mori Y, Akita W, Takada S, Kuyama T, Ohnishi T, et al. Effects of sevelamer hydrochloride on mortality, lipid abnormality and arterial stiffness in hemodialyzed patients: a propensity-matched observational study. Clin Exp Nephrol. 2012;16(6):930–937. doi: 10.1007/s10157-012-0640-4.
    1. Di Iorio B, Bellasi A, Russo D, INDEPENDENT Study Investigators Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol. 2012;7(3):487–493. doi: 10.2215/CJN.03820411.
    1. Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int. 1999;55(1):299–307. doi: 10.1046/j.1523-1755.1999.00240.x.
    1. Nikolov IG, Joki N, Maizel J, Lacour B, Drüeke TB, Massy ZA. Pleiotropic effects of the non-calcium phosphate binder sevelamer. Kidney Int. 2006;70:S16–S23. doi: 10.1038/sj.ki.5001994.
    1. Rastogi A. Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease. Ther Adv Cardiovasc Dis. 2013;7(6):322–342. doi: 10.1177/1753944713513061.
    1. Ikee R, Tsunoda M, Sasaki N, Sato N, Hashimoto N. Emerging effects of sevelamer in chronic kidney disease. Kidney Blood Press Res. 2013;37(1):24–32. doi: 10.1159/000343397.
    1. Caglar K, Yilmaz MI, Saglam M, Cakir E, Acikel C, Eyileten T, et al. Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol. 2008;3(1):61–68. doi: 10.2215/CJN.02810707.
    1. Brandenburg VM, Schlieper G, Heussen N, Holzmann S, Busch B, Evenepoel P, et al. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrol Dial Transplant. 2010;25(8):2672–2679. doi: 10.1093/ndt/gfq053.
    1. Lin HH, Liou HH, Wu MS, Lin CY, Huang CC. Long-term sevelamer treatment lowers serum FGF23 accompanied with increasing serum KlothoLevels in chronic hemodialysis patients. Nephrology. 2014;19(11):672–8. doi: 10.1111/nep.12319.
    1. Schinke T, Amendt C, Trindl A, Pöschke O, Müller-Esterl W, Jahnen-Dechent W. The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem. 1996;271(34):20789–20796. doi: 10.1074/jbc.271.34.20789.
    1. Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin- A is a systemically acting inhibitor of ectopic calcification. J Clin Invest. 2003;112:357–366. doi: 10.1172/JCI17202.
    1. Haddad M, Tajbakhsh R, Farajollahi M, Qorbani M, Besharat S, Joshaghani HR. Association of serum fetuin-A and biochemical parameters in hemodialysis patients. Saudi J Kidney Dis Transpl. 2014;25(4):769–773. doi: 10.4103/1319-2442.134993.
    1. Jung HH, Kim SW, Han H. Inflammation, mineral metabolism and progressive coronary artery calcification in patients on haemodialysis. Nephrol Dial Transplant. 2006;21:1915–1920. doi: 10.1093/ndt/gfl118.
    1. Manenti L, Vaglio A, Pasquali S. Increased fetuin-A levels following treatment with a vitamin D analog. Kidney Int. 2010;78:1186–1190. doi: 10.1038/ki.2010.357.
    1. Massart A, Debelle FD, Racapé J, Gervy C, Husson C, Dhaene M, et al. Biochemical parameters after cholecalciferol repletion in hemodialysis: results from the VitaDial Randomized Trial. Am J Kidney Dis. 2014;64(5):696–705. doi: 10.1053/j.ajkd.2014.04.020.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa